{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022133","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.846232+00:00","generated_at":"2026-05-16T20:35:20.880341+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biofrontera Q3 revenue $7.0M, net loss $6.6M; closes Ameluz asset purchase","bullets":["Q3 2025 revenues $7.0M (down 22% YoY); 9-month revenues stable at $24.6M vs $24.8M.","Net loss $6.6M vs $5.7M in Q3 2024; Adjusted EBITDA -$6.0M vs -$4.6M.","Closed purchase of all U.S. assets for Ameluz and RhodoLED from Biofrontera AG; earnout reduced to 12-15% of net sales.","Divested Xepi antibiotic cream to Pelthos Pharmaceuticals for $3M closing plus up to $6M milestones.","Cash $3.4M at Sep 30; additional $2.5M received in Oct; runway extended by asset purchase and divestiture."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022133","json":"https://secwatch.observer/filing/0001493152-25-022133.json","markdown":"https://secwatch.observer/filing/0001493152-25-022133.md","text":"https://secwatch.observer/filing/0001493152-25-022133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/0001493152-25-022133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315225022133/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:35:20.880341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}